Pharmaceutical manufacturing

FILE - In this Thursday, March 14, 2008 file photo, a woman rides a bicycle past Changzhou SPL in Changzhou, China. The FDA did not open its first permanent offices in China and India until 2008 and 2009, respectively. That followed dozens of deaths and hundreds of allergic reactions in the U.S. linked to the contaminated blood thinner heparin made at this Chinese facility. (AP Photo/Eugene Hoshiko)
August 28, 2019 - 7:44 pm
WASHINGTON (AP) — U.S. health officials on Wednesday tried to reassure patients that they face very low risks from ongoing contamination problems with widely prescribed blood pressure drugs. Drugmakers have issued more than 50 recalls since last July linked to low levels of a probable cancer-...
Read More
Democratic presidential candidate former Vice President Joe Biden speaks during a campaign event at Keene State College in Keene, N.H., Saturday, Aug. 24, 2019. (AP Photo/Michael Dwyer)
Associated Press
August 27, 2019 - 1:57 pm
WASHINGTON (AP) — Wrapping himself in the legacy of "Obamacare," Joe Biden is offering restless Democrats a health care proposal that goes far beyond it, calling for a government plan almost anybody can join but stopping short of a total system remake. Recent polls show softening support for the...
Read More
Britain's Prime Minister Boris Johnson talks to hospital patient Scarlett Gibbons, 5, during a visit to the Royal Cornwall Hospital in Truro, south-west England, Monday Aug. 19, 2019. Johnson is under increasing pressure Monday to recall Parliament after leaked government documents warned of widespread problems if the U.K. leaves the European Union without a Brexit withdrawal agreement. (Peter Nicholls/Pool via AP)
August 19, 2019 - 4:19 pm
LONDON (AP) — Britain's government plans to call a summit of social media companies to discuss what more they can do to fight online misinformation about vaccines following a spike in measles cases. Although plans for such a gathering were still being worked out, Prime Minister Boris Johnson...
Read More
FILE- In this July 10, 2018, file photo bottles of medicine ride on a belt at a mail-in pharmacy warehouse in Florence, N.J. Drug companies are still raising prices for brand-name prescription medicines, just not as often or by as much as they used to, according to an Associated Press analysis. (AP Photo/Julio Cortez, File)
August 19, 2019 - 1:41 pm
TRENTON, N.J. (AP) — Drug companies are still raising prices for brand-name prescription medicines, just not as often or by as much as they used to, according to an Associated Press analysis. After years of frequent list price hikes, many drugmakers are showing some restraint, according to the...
Read More
FILE - In this July 30, 2019, file photo, Sen. Bernie Sanders, I-Vt., speaks during a Democratic presidential primary debate in Detroit. Sanders and other progressives seeking the Democratic presidential nomination are zeroing in on pharmaceutical and insurer profits, money they say would be better spent providing health care for everyone under “Medicare for All.” But research by The Associated Press suggests those dollars might not go so far. (AP Photo/Paul Sancya, file)
August 11, 2019 - 4:40 am
WASHINGTON (AP) — Sen. Bernie Sanders and other progressive Democratic presidential candidates are zeroing in on pharmaceutical and insurer profits, money they say would be better spent providing health care for everyone under "Medicare for All." Health care dollars from government programs,...
Read More
This photo provided by Novartis shows their gene therapy medicine Zolgensma. U.S. regulators want to know why Novartis didn't disclose a problem with testing data until after they approved the Swiss drugmaker’s $2.125 million gene therapy. On Tuesday, Aug. 6, 2019, the Food and Drug Administration said the questionable data involves testing of the therapy, Zologensma, on animals, not on patients. (Novartis via AP)
August 06, 2019 - 3:24 pm
TRENTON, N.J. (AP) — U.S. regulators want to know why Novartis didn't disclose a problem with testing data until after the Swiss drugmaker's $2.1 million gene therapy was approved. The Food and Drug Administration said Tuesday the manipulated data involved testing in animals, not patients, and it's...
Read More
Traders Gregory Rowe, left, and Daniel Kryger, center, work with specialist Mario Picone on the floor of the New York Stock Exchange, Tuesday, Aug. 6, 2019. Stock markets turned higher on Tuesday as China stabilized its currency after allowing it to depreciate against the dollar in response to President Donald Trump's decision to put more tariffs on Chinese goods. (AP Photo/Richard Drew)
August 06, 2019 - 12:44 pm
Technology and bank companies helped drive stocks broadly higher on Wall Street Tuesday as the market regained its footing a day after posting its biggest decline of the year. The bounce came as investors welcomed China's decision to stabilize its currency, easing some of the pressure in its trade...
Read More
FILE - In this Wednesday, July 10, 2019, file photo, President Donald Trump speaks about kidney health, accompanied by Health and Human Services Secretary Alex Azar, left, in Washington. Azar says he and Trump are working on a plan to allow Americans to import lower-priced prescription drugs from Canada. (AP Photo/Alex Brandon, File)
July 31, 2019 - 12:19 pm
WASHINGTON (AP) — The Trump administration said Wednesday it will create a way for Americans to legally and safely import lower-cost prescription drugs from Canada for the first time, reversing years of refusals by health authorities amid a public outcry over high prices for life-sustaining...
Read More
FILE - This May 1, 2018 file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck & Co. reports earnings Friday, Feb. 1, 2019. Merck & Co., Inc. reports financial results on Tuesday, July 30, 2019. (AP Photo/Seth Wenig, File)
July 30, 2019 - 4:00 am
KENILWORTH, N.J. (AP) — Merck is reporting a 12% jump in global sales, pushing it past profit expectations for the second quarter. The pharmaceutical company reported a profit of $2.67 billion, or $1.03 per share. Earnings, adjusted for costs related to mergers and acquisitions and restructuring...
Read More
FILE - In this July 8, 2016, file photo, a prescription is filled at Pucci's Pharmacy in Sacramento, Calif. Four pharmaceutical companies are agreeing to pay California nearly $70 million to settle allegations that they delayed drugs to keep prices high. California Attorney General Xavier Becerra said Monday, July 29, 2019, that the bulk of the money will come from Teva Pharmaceutical Industries for paying to delay a generic narcolepsy drug from entering the market for nearly six years. (AP Photo/Rich Pedroncelli, File)
July 29, 2019 - 12:59 pm
SACRAMENTO, Calif. (AP) — Four pharmaceutical companies collectively are agreeing to pay California nearly $70 million to settle allegations that they delayed drugs to keep prices high, California Attorney General Xavier Becerra said Monday. The bulk of the money will come from Teva Pharmaceutical...
Read More

Pages